Providence Capital Advisors’s Novo Nordisk NVO Stock Holding History

Providence Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18	Closed	-$1.22K	–	328
2022 Q4	$1.22K	Hold	18	–	–	﹤0.01%	265
2022 Q3	$1K	Buy	+18	New	+$964	﹤0.01%	302
2022 Q1	–	Sell	-1,432	Closed	-$80K	–	499
2021 Q4	$80K	Sell	1,432 -3,698	-72%	-$200K	0.02%	134
2021 Q3	$246K	Hold	5,130	–	–	0.08%	103
2021 Q2	$215K	Sell	5,130 -720	-12%	-$27.9K	0.07%	106
2021 Q1	$197K	Hold	5,850	–	–	0.07%	102
2020 Q4	$204K	Buy	+5,850	New	+$202K	0.08%	98
2019 Q1	–	Sell	-1,080	Closed	-$25K	–	320
2018 Q4	$25K	Hold	1,080	–	–	0.02%	154
2018 Q3	$25K	Hold	1,080	–	–	0.02%	160
2018 Q2	$25K	Hold	1,080	–	–	0.02%	148
2018 Q1	$27K	Sell	1,080 -212	-16%	-$5.57K	0.02%	139
2017 Q4	$35K	Buy	+1,292	New	+$32.9K	0.03%	130

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Providence Capital Advisors's NVO Position: Q1 2023 in Review

Providence Capital Advisors sold out of Novo Nordisk (NVO) in Q1 2023, closing a stake of 18 shares — an estimated $1.22K sold.

Providence Capital Advisors first reported a position in NVO in Q4 2017 and held it in 12 quarters. The position peaked at $246K in Q3 2021. 1,146 funds tracked by Wall St. Rank hold NVO as of Q1 2023.

Providence Capital Advisors reported no remaining Novo Nordisk position as of Q1 2023 after selling out during the quarter.
Providence Capital Advisors sold 18 Novo Nordisk shares in Q1 2023, an estimated $1.22K.
Providence Capital Advisors first reported a position in Novo Nordisk in Q4 2017 and held it in 12 quarters.
Providence Capital Advisors's Novo Nordisk position peaked at $246K in Q3 2021.
1,146 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2023.

Based on Providence Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.